Ji’an, Jiangxi, China, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into a strategic cooperation agreement (the “Agreement”) with Jinggangshan University (“JGSU”), a public university located in Ji'an City of Jiangxi Province, for a study on the chemical constituents of Liparis Odorata, a traditional Chinese medicine, for the treatment of hyperlipidemia.
Under the Agreement, JGSU agrees to conduct the aforementioned studies and provide scientific research results to the Company, and report to the Company upon completion within 24 months from the date of the Agreement.
Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are excited to collaborate with JGSU on this research partnership since JGSU has an impressive track record of cutting-edge research in studies of Chinese medicines, and its expertise and resources will be invaluable to us. It is critical that pharmaceutical companies and academic institutions work together to develop Chinese medicine for diseases with significant unmet market and medical needs, and JGSU is one of the ideal partners to support us in this effort. Working with JGSU, we expect to be at the forefront of developing Chinese medicines with better efficacy and market recognition.”
Established in 1958 and located in the Jinggangshan Mountains in Qingyuan District, Ji'an city of Jiangxi province in China, JGSU is jointly supported by the Ministry of Education of the People's Republic of China and the People's Government of Jiangxi Province and pair-assisted by Tongji University. In July 2003, approved by the Ministry of Education of the People’s Republic of China, Jinggangshan Normal University was renamed to Jinggangshan University by joining Jinggangshan Medicine College and Jinggangshan Vocational Technical College. The Medical School of Jinggangshan University possesses a Level 3A graded affiliated hospital, the Jinggangshan University Affiliated Hospital, which consists of 35 medical departments and sections and is listed in World Health Organization, Foundation for Advancement of International Medical Education and Research (FAIMER), the Geneva Foundation for Medical Education and Research (GFMER), as well as the AVICENNA Directory for medicine. For more information, visit the company’s website at http://www.jgsu.edu.cn/.
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For more information, please contact:
Ascent Investors Relations LLC Tina Xiao President Phone: 917-609-0333 Email: tina.xiao@ascent-ir.com
Recovering from a three-day sell-off, shares of Chinese e-commerce giant Alibaba Group Holding Limited (NYSE: BABA) stock bounced back on Thursday and are up 7.2% as of 11:11 a.m. ET. Alibaba's bounce back appears tied to a Bloomberg report yesterday that the company is "weighing options" to dispose of its 30% stake in Weibo (NASDAQ: WB), the "Chinese Twitter," and may sell its Weibo shares to "a state-owned firm." There are at least a couple of reasons why such a move could be good for Alibaba.
Pinterest (NYSE: PINS) had a rough go of it in 2021. Let's look closer at its prospects and determine if Pinterest's stock has a chance to hit $100 in 2022. Topmost of the reasons for Pinterest's stock decline has been the downward trend in monthly active users (MAU) as economies reopened.
The need of a robust charging infrastructure to support the growth of electric vehicles (EVs) is undisputed. What isn't as clear is which players will be instrumental in developing this infrastructure and, more importantly, whether can they do this profitably. Let's discuss which of the two top EV charging stocks, ChargePoint (NYSE: CHPT) and Blink Charging (NASDAQ: BLNK), is a better buy right now.
We recommended CLF in October, so let's see if the stock is a magnet for new buyers -- and whether holders should keep their steely resolve.
Let’s talk about losses. Specifically, let’s talk about individual stock losses during a time of generally rising markets. While these situations can define stocks that are fundamentally unsound, they can also highlight stocks that are primed for rapid gains. To start with, we’re still in a long-term bullish trend. It got started back in March of 2020, when the economy hit bottom during the initial stage of the pandemic crisis. Since then, that first bounce back up has turned into a strong and s
The bank suggests going overweight on these sectors to avoid negative returns.
Warren Buffett's Berkshire Hathaway portfolio provides a mix of legacy and current investments. Fortunately, some companies in Buffett's portfolio continue to hold potential for investor returns. Investors wanting meaningful growth should consider companies such as Amazon (NASDAQ: AMZN), Apple (NASDAQ: AAPL), and Verizon (NYSE: VZ).
There are a lot more people sick with COVID-19 today than ever before, but evidence is piling up to suggest the surging omicron variant is less severe than the previously dominant delta variant.
Wood believes we're still in a strong bull market. Take advantage.
Yahoo Finance Live's Brian Sozzi and Julie Hyman break down Citi's move to raise the price targets for key EV players Tesla, Ford, and GM, in addition to looking at the slumps Chinese tech companies are experiencing and Biogen's stock following after Samsung rebuts reports of acquisition.
The explosive price action on meme stocks like AMC (NYSE: AMC) and Gamestop (NYSE: GME) in 2021 put the idea of a "short squeeze" on the minds of retail investors, who are now looking for the next potential stock that might vault higher. While these meme stocks ended up being extreme squeezes, to a lesser extent short-sellers have beaten down insurance tech company Lemonade (NYSE: LMND) as well. What is a short squeeze?
History and multiple data points suggest that a stock market crash or a steep correction could be on the horizon. If you're an investor who grimaces at the thought of market volatility, buying safe stocks is a good way to ensure you'll sleep well at night. First up is electric utility stock NextEra Energy (NYSE: NEE).
You don't have to be a millionaire -- or even a thousandaire -- to buy these two veteran companies with bright futures.
The year is winding down, and it’s time for Wall Street’s analysts to flag their top picks for the coming year. It’s a time-honored tradition, in most walks of life, to take a sometimes tongue-in-cheek look at what lies ahead, and to start giving advice on the say-so of a metaphorical crystal ball. Analysts have been analyzing each stock carefully, looking at its past and current performance, its trends on a variety of time frames, management’s plans – the analysts take everything into account.
Analyst Itay Michaeli's new price target for Tesla is $262, which is well below Wall Street's mean consensus.
Losing money in the S&P 500 is never fun. But it stings all the more when everyone else is making tons on their stocks.
DraftKings is one of the top IPO stocks to watch, as gambling legalization gains steam. Here is what the fundamentals and technical analysis say about buying DKNG stock now.
The data don’t lie: Since 1871, according to data from Yale University’s Robert Shiller, the S&P 500’s (SPX) dividends per share (DPS) have grown at a 3.7% annualized pace. Don’t try to dismiss dividends’ robust growth rate on the grounds that it traces largely to the early years in Shiller’s 150-year database. A similar story is told by the volatility of DPS’ and EPS’ growth rates.
The English physicist Isaac Newton's first law of motion can also indirectly be applied to dividend investing. Newton's physics standard, which says an object in motion tends to stay in motion, applies to how management at most companies tends to view dividends. To paraphrase, a dividend that is growing each year tends to stay growing with each passing year.
These three stocks are core holdings in my portfolio, and new investors should consider doing the same.